Literature DB >> 20534046

Review article: phenytoin use and efficacy in the ED.

Katharine Gallop1.   

Abstract

This article reviews the evidence regarding the use of phenytoin in adult and paediatric patients experiencing seizures in the ED in Australasia, including relevant pharmacokinetics, dosage, therapeutic drug monitoring and methods of administration. It summarizes current evidence regarding the use of phenytoin in a number of seizure types commonly seen in ED. A search of Medline, Embase and Cochrane was performed using appropriate keyword and MeSH headings. A loading dose of phenytoin should be given to phenytoin naïve patients for the emergency treatment of seizures; parenteral administration results in therapeutic concentration sooner than oral administration but is associated with more frequent and significant adverse effects. Diluting phenytoin is safe but there is limited evidence regarding adverse effects of diluted phenytoin; a filter is probably not needed. Free phenytoin concentrations correlate best with antiseizure efficacy. Phenytoin is used in the treatment of status epilepticus although evidence here is limited; it may also be given to prevent early post-traumatic seizures. It should not be given to treat or prevent eclamptic or alcohol-related seizures. There is insufficient evidence regarding its use in preventing febrile convulsions, treating or preventing seizures due to space occupying lesions or intracerebral haemorrhage and thrombosis. In conclusion, phenytoin is appropriate for treatment of some seizures seen in the ED; it is associated with significant adverse effects; trials are ongoing regarding the use of other anticonvulsants in the treatment of status epilepticus.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20534046     DOI: 10.1111/j.1742-6723.2010.01269.x

Source DB:  PubMed          Journal:  Emerg Med Australas        ISSN: 1742-6723            Impact factor:   2.151


  5 in total

1.  Phenytoin as an effective treatment for polymorphic ventricular tachycardia due to QT prolongation in a patient with multiple drug intolerances.

Authors:  Neil Yager; Katherine Wang; Najiba Keshwani; Mikhail Torosoff
Journal:  BMJ Case Rep       Date:  2015-06-12

2.  Levetiracetam as an alternative to phenytoin for second-line emergency treatment of children with convulsive status epilepticus: the EcLiPSE RCT.

Authors:  Richard E Appleton; Naomi Ea Rainford; Carrol Gamble; Shrouk Messahel; Amy Humphreys; Helen Hickey; Kerry Woolfall; Louise Roper; Joanne Noblet; Elizabeth Lee; Sarah Potter; Paul Tate; Nadia Al Najjar; Anand Iyer; Vicki Evans; Mark D Lyttle
Journal:  Health Technol Assess       Date:  2020-11       Impact factor: 4.014

3.  Emergency treatment with levetiracetam or phenytoin in status epilepticus in children-the EcLiPSE study: study protocol for a randomised controlled trial.

Authors:  Mark D Lyttle; Carrol Gamble; Shrouk Messahel; Helen Hickey; Anand Iyer; Kerry Woolfall; Amy Humphreys; Naomi E A Bacon; Louise Roper; Franz E Babl; Stuart R Dalziel; Mary Ryan; Richard E Appleton
Journal:  Trials       Date:  2017-06-19       Impact factor: 2.279

4.  Clinical Efficacy and Safety of Injectable Levetiracetam Versus Phenytoin as Second-Line Therapy in the Management of Generalized Convulsive Status Epilepticus in Children: An Open-Label Randomized Controlled Trial.

Authors:  Nuzhat Noureen; Saadia Khan; Asim Khursheed; Imran Iqbal; Moallah Maryam; Syed Muhammad Sharib; Neeta Maheshwary
Journal:  J Clin Neurol       Date:  2019-10       Impact factor: 3.077

Review 5.  The Impact of Anti-Epileptic Drugs on Growth and Bone Metabolism.

Authors:  Hueng-Chuen Fan; Herng-Shen Lee; Kai-Ping Chang; Yi-Yen Lee; Hsin-Chuan Lai; Pi-Lien Hung; Hsiu-Fen Lee; Ching-Shiang Chi
Journal:  Int J Mol Sci       Date:  2016-08-01       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.